Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Chugai Claims 1st-Ever Title in Japan Pharma Market in 2021 on Brisk Oncologic Performance: IQVIA
February 18, 2022
- Sawai to Launch Teribone Generic as Court Invalidates Patents; Asahi Kasei to Challenge Ruling
February 17, 2022
- GSK Launches Benlysta Observational Study in SLE Patients with History of Lupus Nephritis
February 17, 2022
- Healios Plans Preapplication Consultation with PMDA on MultiStem as Early as March
February 17, 2022
- GMP Issues Likely to Trigger Ozempic Supply Restrictions in Japan: Novo
February 16, 2022
- Padcev Shows 36.4% Pathologic Complete Response in Bladder Cancer
February 16, 2022
- Opdivo Approved for 5 New Indications in South Korea
February 16, 2022
- Bayer Employee Loses in Damage Suit over Xarelto Scandal
February 15, 2022
- Pharma Officials Air Hopes and Concerns as Japan Moves to Enhance Supply Chain for Economic Security
February 15, 2022
- MSD Japan Boosts COVID-19 Pill Supply to 800,000 Courses by March
February 15, 2022
- Taiho Files TS-1 for Adjuvant Chemo in Breast Cancer in Japan
February 15, 2022
- Meiji Ditches Ziprasidone Schizophrenia Program in Japan
February 15, 2022
- Chugai to Integrate 2 Chinese Subsidiaries in April
February 15, 2022
- Otsuka’s 4 Global Brands Fare Well to Hit 2023 Target 2 Years Earlier
February 14, 2022
- Chugai Joins Top Ranks in Japan Sales on Ronapreve Boon, Roche Collaboration
February 14, 2022
- Sanofi Files NDA for Rare Blood Disease Drug in Japan
February 14, 2022
- Shionogi, Chiba Univ. Tie Up for Nasal Vaccine Research, Eye COVID-19 Trial in FY2022
February 14, 2022
- Eisai Formally Opposes CMS Coverage Proposal for Aduhelm
February 14, 2022
- Astellas Set to Forge High-Quality Sales Scheme with Global Know-How, Double Online Reps
February 10, 2022
- Lusefi OD Film Approved in Japan: Taisho
February 10, 2022
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…